



# EUCAST

European Committee  
on Antimicrobial  
Susceptibility Testing

## Public Consultation

---

# Proposed revision of breakpoints for meropenem against *Pseudomonas* and *Acinetobacter* species

28 April 2026

Please send comments to the EUCAST Scientific Secretary at [Mandy.Wootton@wales.nhs.uk](mailto:Mandy.Wootton@wales.nhs.uk) by 01 June 2026.

### Background

The recent consultation on breakpoints for carbapenems (27 Jan. 2026, closed 15 Mar. 2026) included a suggestion by the Swedish NAC (SRGA) that the breakpoints for meropenem in *Pseudomonas* spp. and *Acinetobacter* spp. should not include the S, susceptible standard dose, but only the I, susceptible, increased exposure category. EUCAST accepted this proposal since significant infections with these organisms tend to occur in compartments that are difficult to reach and therefore often need high-dose therapy. This opinion is also corroborated by large trials [1,2]. If approved, the breakpoints will be effective with version 16.1 of the breakpoint tables.



## Public Consultation

---

### Meropenem

Species	ECOFF	Current breakpoints (v 15.0, 2025)	New breakpoints
<i>Pseudomonas</i> spp.	2	2/8	0.001/4
<i>Acinetobacter</i> spp	2	2/8	0.001/4

### Susceptibility testing

#### Literature

- [1] Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. *The Lancet Infectious Diseases* 2021;21:213–25. [https://doi.org/10.1016/S1473-3099\(20\)30731-3](https://doi.org/10.1016/S1473-3099(20)30731-3).
- [2] Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. *The Lancet Infectious Diseases* 2018;18:391–400. [https://doi.org/10.1016/S1473-3099\(18\)30099-9](https://doi.org/10.1016/S1473-3099(18)30099-9).